Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Mar;38(3):455–459. doi: 10.1128/aac.38.3.455

Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora.

M Ritz 1, H Lode 1, M Fassbender 1, K Borner 1, P Koeppe 1, C E Nord 1
PMCID: PMC284479  PMID: 8203837

Abstract

In a randomized, double-blind, placebo-controlled, multiple-dose pharmacokinetic study, the safety and effect on intestinal flora of sparfloxacin (SPX) were determined in 12 healthy male volunteers (8 received SPX and 4 received a placebo). Following fasting and oral administration of 400 mg on day 1 and 200 mg on days 2 to 8, concentrations of the free drug in serum, urine, and feces were measured by high-performance liquid chromatography; serum and urine were also evaluated by a microbiological assay. All results, except those for renal excretion, exclude the glucuroconjugate metabolite. A mean peak concentration in serum (400-mg dose) of 0.56 +/- 0.13 mg/liter was measured 3.52 +/- 0.98 h after administration. Pharmacokinetic parameters (measured by high-performance liquid chromatography) were based on an open, one-compartment model and resulted in the following day 1 (calculated for the 200-mg dose), day 4 (recalculated for a single dose), and day 8 values (mean +/- standard deviation): area under the curve, 16.4 +/- 2.3 (day 1) and 18.3 +/- 5.1 (day 4) mg.h/liter; elimination half-life, 18.3 +/- 3.9 h; steady-state volume of distribution, 4.7 +/- 1.4 (day 1) and 4.3 +/- 1.2 (day 8) liters/kg; apparent total clearance, 201 +/- 31 (day 1) and 190 +/- 51 (day 4) ml/min; renal clearance, 19.1 +/- 5.8 (day 1) and 23.2 +/- 19.4 (day 4) ml/min. Recovery in urine on day 1 was 5.89% +/- 1.4% of the dose in 24 h for the parent compound and 18.4% +/- 6.8% for the SPX glucuronide.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
455

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aronsson B., Möllby R., Nord C. E. Diagnosis and epidemiology of Clostridium difficile enterocolitis in Sweden. J Antimicrob Chemother. 1984 Dec;14 (Suppl 500):85–95. doi: 10.1093/jac/14.suppl_d.85. [DOI] [PubMed] [Google Scholar]
  2. Averdunk R., Borner K. Korrelation der Thromboplastinzeiten bei Dicumarol-behandelten Patienten unter Verwendung verschiedener Thrombokinase-Präparate. Z Klin Chem Klin Biochem. 1970 May;8(3):263–268. [PubMed] [Google Scholar]
  3. Benet L. Z. Effect of route of administration and distribution on drug action. J Pharmacokinet Biopharm. 1978 Dec;6(6):559–585. doi: 10.1007/BF01062110. [DOI] [PubMed] [Google Scholar]
  4. Bennett J. V., Brodie J. L., Benner E. J., Kirby W. M. Simplified, accurate method for antibiotic assay of clinical specimens. Appl Microbiol. 1966 Mar;14(2):170–177. doi: 10.1128/am.14.2.170-177.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Borner K., Borner E., Lode H. Determination of sparfloxacin in serum and urine by high-performance liquid chromatography. J Chromatogr. 1992 Sep 2;579(2):285–289. doi: 10.1016/0378-4347(92)80393-5. [DOI] [PubMed] [Google Scholar]
  6. Brumfitt W., Franklin I., Grady D., Hamilton-Miller J. M., Iliffe A. Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. Antimicrob Agents Chemother. 1984 Nov;26(5):757–761. doi: 10.1128/aac.26.5.757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cohen M. A., Huband M. D., Mailloux G. B., Yoder S. L., Roland G. E., Heifetz C. L. In vitro activity of sparfloxacin (CI-978, AT-4140, and PD 131501). A quinolone with high activity against gram-positive bacteria. Diagn Microbiol Infect Dis. 1991 Sep-Oct;14(5):403–415. doi: 10.1016/0732-8893(91)90067-p. [DOI] [PubMed] [Google Scholar]
  8. Cooper M. A., Andrews J. M., Ashby J. P., Matthews R. S., Wise R. In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent. J Antimicrob Chemother. 1990 Nov;26(5):667–676. doi: 10.1093/jac/26.5.667. [DOI] [PubMed] [Google Scholar]
  9. Greenblatt D. J., Koch-Weser J. Clinical pharmacokinetics (second of two parts). N Engl J Med. 1975 Nov 6;293(19):964–970. doi: 10.1056/NEJM197511062931905. [DOI] [PubMed] [Google Scholar]
  10. Heimdahl A., Nord C. E. Effect of phenoxymethylpenicillin and clindamycin on the oral, throat and faecal microflora of man. Scand J Infect Dis. 1979;11(3):233–242. doi: 10.3109/inf.1979.11.issue-3.11. [DOI] [PubMed] [Google Scholar]
  11. Holt H. A., Lewis D. A., White L. O., Bastable S. Y., Reeves D. S. Effect of oral ciprofloxacin on the faecal flora of healthy volunteers. Eur J Clin Microbiol. 1986 Apr;5(2):201–205. doi: 10.1007/BF02013987. [DOI] [PubMed] [Google Scholar]
  12. Koeppe P., Hamann C. A program for non-linear regression analysis to be used on desk-top computers. Comput Programs Biomed. 1980 Dec;12(2-3):121–128. doi: 10.1016/0010-468x(80)90058-6. [DOI] [PubMed] [Google Scholar]
  13. Kojima T., Inoue M., Mitsuhashi S. In vitro activity of AT-4140 against clinical bacterial isolates. Antimicrob Agents Chemother. 1989 Nov;33(11):1980–1988. doi: 10.1128/aac.33.11.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Matsunaga Y., Miyazaki H., Oh-e Y., Nambu K., Furukawa H., Yoshida K., Hashimoto M. Disposition and metabolism of [14C]sparfloxacin in the rat. Arzneimittelforschung. 1991 Jul;41(7):747–759. [PubMed] [Google Scholar]
  15. Murray B. E. Quinolones and the gastrointestinal tract. Eur J Clin Microbiol Infect Dis. 1989 Dec;8(12):1093–1101. doi: 10.1007/BF01975176. [DOI] [PubMed] [Google Scholar]
  16. Nakamura S., Kurobe N., Ohue T., Hashimoto M., Shimizu M. Pharmacokinetics of a novel quinolone, AT-4140, in animals. Antimicrob Agents Chemother. 1990 Jan;34(1):89–93. doi: 10.1128/aac.34.1.89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Nakamura S., Minami A., Nakata K., Kurobe N., Kouno K., Sakaguchi Y., Kashimoto S., Yoshida H., Kojima T., Ohue T. In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone. Antimicrob Agents Chemother. 1989 Aug;33(8):1167–1173. doi: 10.1128/aac.33.8.1167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Neu H. C. Quinolone antimicrobial agents. Annu Rev Med. 1992;43:465–486. doi: 10.1146/annurev.me.43.020192.002341. [DOI] [PubMed] [Google Scholar]
  19. Nord C. E., Edlund C. Impact of antimicrobial agents on human intestinal microflora. J Chemother. 1990 Aug;2(4):218–237. doi: 10.1080/1120009x.1990.11739021. [DOI] [PubMed] [Google Scholar]
  20. Reeves D. S. The effect of quinolone antibacterials on the gastrointestinal flora compared with that of other antibacterials. J Antimicrob Chemother. 1986 Nov;18 (Suppl 500):89–102. doi: 10.1093/jac/18.supplement_d.89. [DOI] [PubMed] [Google Scholar]
  21. Simor A. E., Fuller S. A., Low D. E. Comparative in vitro activities of sparfloxacin (CI-978; AT-4140) and other antimicrobial agents against staphylococci, enterococci, and respiratory tract pathogens. Antimicrob Agents Chemother. 1990 Nov;34(11):2283–2286. doi: 10.1128/aac.34.11.2283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Wolfson J. S., Hooper D. C. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev. 1989 Oct;2(4):378–424. doi: 10.1128/cmr.2.4.378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Wolfson J. S., Hooper D. C. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother. 1985 Oct;28(4):581–586. doi: 10.1128/aac.28.4.581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Wolfson J. S. Quinolone antimicrobial agents: adverse effects and bacterial resistance. Eur J Clin Microbiol Infect Dis. 1989 Dec;8(12):1080–1092. doi: 10.1007/BF01975175. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES